Such a move would further delay any rollout of AstraZeneca shots in the U.S., where the vaccine has already been made and stockpiled. The emergency-use application allowed all three to win quicker FDA approval in the pandemic. The AstraZeneca shot has also been linked in Europe and elsewhere to very rare, but sometimes-fatal, serious blood clotting, an issue that European regulators, AstraZeneca and outside researchers are still studying. The U.S. has ordered so many doses of already-approved shots that there is little urgency in rolling out the AstraZeneca vaccine domestically. That is a big factor in the company’s discussions with U.S. government and FDA officials, the people familiar with the discussions say.

Source: Mint May 08, 2021 12:00 UTC